-
BPL Supports the Immune Deficiency Foundation Research Grant Program for Second Year in a Row
November 02, 2022 -
10/10 Marks A Day to Bring Awareness to One of The Rarest Bleeding Disorders
October 10, 2022 -
The X Factor: Elevating the Voices of Rare Disease Patients Has Never Been More Vital
October 10, 2022 -
BPL Recognized as ‘Fast 50 Company’ for the Third Year Running
September 26, 2022 -
Permira Funds and the Marcucci Family Complete Investment in Kedrion and BPL and Announce Appointment of Ugo Di Francesco as CEO
September 01, 2022 -
Hereditary Factor X Deficiency (HFXD) Survey Shows Unmet Need in Patients With Rare Bleeding Disorder
August 16, 2022 -
BPL USA Awarded as a “Best Place to Work”
July 26, 2022 -
BPL Celebrates World Blood Donor Day
June 14, 2022 -
BPL Expands Options for Patients in the Dominican Republic With Marketing Authorization for Coagadex®
May 31, 2022 -
BPL Receives Orphan Drug Marketing Authorization for Coagadex® in Mexico
May 04, 2022 -
BPL Marks Bleeding Disorders Awareness Month 2022
March 31, 2022 -
BPL Granted a New Patent in the US
March 30, 2022 -
BPL Supports Rare Disease Day 2022
February 28, 2022 -
BPL Full Year 2021 Results: BPL Delivers Another Strong Performance
February 07, 2022 -
BPL Affiliate Makes First Ever Sale to Mexico
February 04, 2022 -
BPL Granted Licence From the National Medical Products Administration (NMPA) to Market ALBUMINEX® 25% Product to China
January 24, 2022 -
Permira Acquires Kedrion and BPL
January 20, 2022 -
BPL to Support the Immune Deficiency Foundation Research Grant Program
October 12, 2021 -
Second Annual Hereditary Factor 10 Deficiency Awareness Day Kicks Off October 10
October 08, 2021 -
BPL Announces the Kick-off of the Hereditary Factor X Deficiency in America Survey
September 28, 2021 -
BPL Recognized as 'Fast 50 Company' for the Second Year Running
September 20, 2021 -
BPL Delivers a Strong Performance in Its 1st Half 2021 Results
July 23, 2021 -
EU Health Commissioner Says Plasma Donation Plays a Vital Role
June 14, 2021 -
Bio Products Laboratory Support for Strong Trade Links with India
May 04, 2021 -
BPL and Atlantic Research Group Enter Into Long-Term Collaboration
April 28, 2021 -
Bio Products Laboratory: £23m Investment in New 1,000 Square Meter Filling and Sterilisation Facility at Elstree
March 29, 2021 -
BPL Sells 25 US Plasma Centres to Grifols for $370 million
March 01, 2021 -
Bio Products Laboratory Receives Triangle Business Journal’s Fast 50 Award
October 19, 2020 -
BPL Announces October 10th Hereditary Factor X Deficiency Awareness Day
October 08, 2020 -
Bio Products Laboratory USA Recognized as Triangle Business Journal’s Best Places to Work
September 14, 2020 -
Fourth Update on BPL’s Continued Efforts During the COVID-19 Pandemic
June 05, 2020 -
Bio Products Laboratory Announces Launch of ALBUMINEX® 5% and ALBUMINEX® 25% With Supply Immediately Available in the United States
May 27, 2020 -
Third Update on BPL’s Work to Ensure the Provision of Critical Medicines in Response to the COVID-19 Pandemic
May 06, 2020 -
Further Update on BPL’s Actions to Ensure the Provision of Critical Medicines in Response to the Worldwide COVID-19 Pandemic
April 07, 2020 -
Global Plasma Leaders Collaborate to Accelerate Development of Potential Covid-19 Hyperimmune Therapy
April 06, 2020 -
COVID-19 and Update on Actions Taken to Ensure Patient Needs Will Continue to be Met
March 18, 2020 -
FDA Approves Bio Products Laboratory’s Gammaplex® 10% for Treatment of Primary immunodeficiency and Chronic Immune Thrombocytopenic Purpura
February 07, 2017 -
Bio Products Laboratory Receives European Approval for Coagadex® (Human Coagulation Factor X)
March 30, 2016 -
Bio Products Laboratory Announces Supply of COAGADEX® Now Available in the United States
December 03, 2015 -
Press Release: Bio Products Laboratory Receives FDA approval for Coagadex® (Coagulation Factor X, Human) First-ever FDA-approved treatment for hereditary factor X deficiency
October 21, 2015 -
Press Release: Gammaplex® Approved For Use In Pediatric Patients
October 21, 2015 -
Press Release: FDA Accepts BPL’s Amended BLA Submission for Coagadex® (Coagulation Factor X, Human)
May 27, 2015 -
Press Release: Bio Products Laboratory, Ltd. Announces Results from Phase III Registration Study of its Factor X Coagulation Product
April 17, 2015 -
Bio Products Laboratory Inc. (BPL) Announces NEW Vial Size of Gammaplex® for the Treatment of Primary Immunodeficiency and Chronic Immune Thrombocytopenic Purpura
June 16, 2014 -
Press Release: Change of name to BPL Holdings for Plasma Resources UK
January 01, 2014 -
Press Release: BPL Announces Strong Progress on the World’s First Licensed Factor X Product
December 31, 2013 -
Press Release: Change of Ownership
September 01, 2013 -
Parliamentary Year Book
January 28, 2013 -
Press Release on Investment Request
September 01, 2012 -
Approval Letter - Gammaplex
September 17, 2009